Abacavir and hypersensitivity

HIV-drug abacavir linked to fatal hypersensitivity reactions.

August 8, 2000

NEW YORK, July 31 (Praxis Press) Ziagen (abacavir) is an oral, guanosine nucleoside reverse transcriptase inhibitor approved for the treatment of HIV infection. Recently the drug's manufacturer, Glaxo Wellcome, notified physicians of cases of fatal hypersensitivity reactions in patients reintroduced the drug. The letter, posted on the US Food and Drug Administration's (FDA) web site, states that, "recent reports indicate that severe or fatal hypersensitivity reactions can occur within hours after Ziagen reintroduction in patients who have no identified history or unrecognized symptoms of hypersensitivity to Ziagen therapy." The letter advises physicians not to reintroduce Ziagen to patients who discontinued the drug because of hypersensitivity. The letter also warns that even if symptoms consistent with hypersensitivity are not identified, reintroduction should be undertaken with caution.

Popular Now

  1. Henrietta Lacks’s Family Seeks Compensation
  2. Broad Wins CRISPR Patent Interference Case
    Daily News Broad Wins CRISPR Patent Interference Case

    The USPTO’s Patent Trial and Appeal Board has ruled in favor of the Broad Institute of MIT and Harvard retaining intellectual property rights covered by its patents for CRISPR gene-editing technology.

  3. Humans Never Stopped Evolving
    Features Humans Never Stopped Evolving

    The emergence of blood abnormalities, an adult ability to digest milk, and changes in our physical appearance point to the continued evolution of the human race.

  4. Abundant Sequence Errors in Public Databases
Business Birmingham